China-Made COVID Antiviral Pill Completes Trial

Image copyright: Reuters

The Spin


Narrative A

China is facing a staggering COVID surge with the rollback of its zero-COVID policy. As cases and deaths increase, this new anti-viral drug will be very helpful, especially as the country experiences a shortage of Paxlovid and other COVID-specific medications.


Narrative B

While VV116 may seem like a promising alternative to Paxlovid, it has not been studied enough. The clinical trials involved too small of a control group, and the results were not clear enough for many authorities and regulators to want to approve or manufacture the drug. It's too early to tell if the new treatment will be able to help China's roiling COVID surge.


Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Sign Up!
Sign Up Now!